Hemostemix Historical Income Statement
HEM Stock | CAD 0.08 0.01 5.88% |
Historical analysis of Hemostemix income statement accounts such as Selling General Administrative of 1.3 M or Total Revenue of 0.0 can show how well Hemostemix performed in making a profits. Evaluating Hemostemix income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Hemostemix's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Hemostemix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Hemostemix is a good buy for the upcoming year.
Hemostemix |
About Hemostemix Income Statement Analysis
Hemostemix Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Hemostemix shareholders. The income statement also shows Hemostemix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Hemostemix Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Hemostemix. It is also known as Hemostemix overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Hemostemix operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Hemostemix is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Hemostemix's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Hemostemix current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hemostemix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Hemostemix's Interest Expense is fairly stable compared to the past year. Selling And Marketing Expenses is likely to climb to about 1.9 M in 2024, whereas Depreciation And Amortization is likely to drop 211.85 in 2024.
Hemostemix income statement Correlations
Click cells to compare fundamentals
Hemostemix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hemostemix income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 1.7K | 2.4K | 1.1K | 495.0 | 223.0 | 211.85 | |
Interest Expense | 105.0K | 106.0K | 10.5K | 350.3K | 550.1K | 577.6K | |
Selling General Administrative | 2.3M | 6.8M | 6.0M | 3.5M | 1.3M | 1.3M | |
Other Operating Expenses | 4.7M | 7.5M | 6.7M | 4.6M | 2.2M | 2.0M | |
Operating Income | (4.7M) | (7.5M) | (6.7M) | (4.6M) | (2.2M) | (2.3M) | |
Net Income From Continuing Ops | (4.9M) | (7.8M) | (6.3M) | (5.2M) | (2.5M) | (2.6M) | |
Ebit | (4.7M) | (7.5M) | (6.7M) | (4.6M) | (2.2M) | (2.3M) | |
Research Development | 2.4M | 650.1K | 179.9K | 622.7K | 384.9K | 365.6K | |
Ebitda | (4.7M) | (7.5M) | (6.7M) | (4.6M) | (2.2M) | (2.3M) | |
Total Operating Expenses | 4.7M | 7.5M | 6.7M | 4.6M | 2.2M | 2.0M | |
Income Before Tax | (4.9M) | (7.8M) | (6.5M) | (4.7M) | (2.5M) | (2.6M) | |
Total Other Income Expense Net | (68.6K) | (189.1K) | 135.2K | 183.5K | (345.1K) | (327.9K) | |
Net Income Applicable To Common Shares | (6.2M) | (4.9M) | (7.8M) | (5.2M) | (4.7M) | (4.9M) | |
Net Income | (4.9M) | (7.8M) | (6.3M) | (5.2M) | (2.5M) | (2.6M) | |
Income Tax Expense | 105.0K | 106.0K | (255.8K) | 486.9K | (3.0) | (2.85) | |
Net Interest Income | (105.0K) | (113.0K) | (20.9K) | (354.0K) | (556.1K) | (528.3K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.